Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06780137 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
A Phase 1 study of Small-cell Lung Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 262
- Enrollment target
- 20
- Study locations
NCT06780137 is a Phase 1 study of Small-cell Lung Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 262 participants, above the 229-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT06780137, a Phase 1 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 262 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated * If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- BIOLOGICAL Gocatamig
- BIOLOGICAL Ifinatamab Deruxtecan (I-DXd)
Study Locations (20)
Region M. de Santiago
- FALP ( Site 2100) - Santiago
- Pontificia Universidad Catolica de Chile ( Site 2102) - Santiago
- Bradfordhill ( Site 2101) - Santiago
Shanghai Municipality
- Shanghai Chest Hospital ( Site 5400) - Shanghai
- Shanghai Pulmonary Hospital ( Site 5405) - Shanghai
Colorado
- University of Colorado Anschutz Medical Campus ( Site 1110) - Aurora
Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111) - Miami
Illinois
- University of Chicago ( Site 1108) - Chicago
Massachusetts
- Dana Farber Cancer Institute ( Site 1105) - Boston
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103) - Hackensack
New York
- Roswell Park Cancer Institute ( Site 1107) - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2030-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06780137
The ClinicalTrials.gov registry entry for NCT06780137 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 229-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (14% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT06780137 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Region M. de Santiago, Shanghai Municipality, Colorado.
Frequently Asked Questions
What is clinical trial NCT06780137 about?
NCT06780137 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)". Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a d...
What is the current status of trial NCT06780137?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 262 participants. The study started on 2025-02-27. Estimated completion is 2030-01-17.
What conditions does trial NCT06780137 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT06780137?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Gocatamig (BIOLOGICAL), Ifinatamab Deruxtecan (I-DXd) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06780137?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06780137 being conducted?
This trial has 20 study locations across Colorado, Florida, Illinois, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.